Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,883,188
  • Shares Outstanding, K 282,147
  • Annual Sales, $ 294,010 K
  • Annual Income, $ 27,730 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales 12.14
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 90.48% (-3.33%)
  • Historical Volatility 35.33%
  • IV Percentile 91%
  • IV Rank 75.73%
  • IV High 98.49% on 12/09/25
  • IV Low 65.51% on 07/18/25
  • Expected Move (DTE 26) 5.19 (18.59%)
  • Put/Call Vol Ratio 1.01
  • Today's Volume 4,690
  • Volume Avg (30-Day) 992
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 17,571
  • Open Int (30-Day) 15,409
  • Expected Range 22.75 to 33.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate 0.00
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.39 +19.45%
on 11/20/25
29.19 -4.28%
on 12/08/25
+4.04 (+16.90%)
since 11/19/25
3-Month
22.86 +22.22%
on 11/07/25
33.65 -16.98%
on 10/07/25
-4.64 (-14.24%)
since 09/19/25

Most Recent Stories

More News
The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute

IRVING, Texas , Dec. 19, 2025 /PRNewswire/ --  Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 27.94 (+0.29%)
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need

IRVING, Texas , Dec. 16, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 27.94 (+0.29%)
Financial Pressure Turns Healthcare AI From Pilots Into Profits

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...

VPT.VN : 0.140 (+21.74%)
CCLD : 3.21 (+0.31%)
ABSI : 3.38 (-0.88%)
LNAI : 1.0500 (+1.94%)
CAI : 27.94 (+0.29%)
VPTDF : 0.0901 (-1.42%)
Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium

IRVING, Texas , Dec. 4, 2025 /PRNewswire/ --  Caris Life Sciences ®  (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 27.94 (+0.29%)
The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute

IRVING, Texas , Dec. 2, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 27.94 (+0.29%)
Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class

IRVING, Texas , Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 27.94 (+0.29%)
Caris Life Sciences to Attend Q4 2025 Investor Conferences

IRVING, Texas , Nov. 17, 2025 /PRNewswire/ --  Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 27.94 (+0.29%)
AI Wellness Market Surges as Personalized Health Platforms Capture Investment Flow

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – AI-powered wellness platforms are commercializing rapidly as major technology companies launch personalized health...

ZBH : 89.13 (-1.40%)
CAI : 27.94 (+0.29%)
CERT : 9.07 (+2.14%)
ACN : 272.25 (+0.85%)
ALEN-U.CN : 1.4500 (unch)
Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Revenue growth of 113% driven by strong performance in molecular profiling services

CAI : 27.94 (+0.29%)
Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response

IRVING, Texas , Oct. 29, 2025 /PRNewswire/ -- Caris Life Sciences ®  (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced...

CAI : 27.94 (+0.29%)

Business Summary

Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving,...

See More

Key Turning Points

3rd Resistance Point 29.03
2nd Resistance Point 28.73
1st Resistance Point 28.34
Last Price 27.94
1st Support Level 27.65
2nd Support Level 27.35
3rd Support Level 26.96

See More

52-Week High 42.50
Fibonacci 61.8% 35.00
Fibonacci 50% 32.68
Fibonacci 38.2% 30.36
Last Price 27.94
52-Week Low 22.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar